100results about How to "Simple nutritional requirements" patented technology

A method for producing L-lactic acid by Bacillus coagulans CGMCC No.2602 belongs to the technical field of microorganisms. In the invention, Bacillus coagulans CGMCC No.2602 is adopted, and under the condition of no oxygen supply, starchiness hydrolyzed sugar or dextrose is fermented by a semicontinuous intermittent fermentation way or an inter-sugar-compensating fermentation way to generate L-lactic acid with high optical purity. The invention has the advantages that the gemma property of the Bacillus coagulans is stable, and the L-lactic acid obtained by inoculating and fermenting the starchiness hydrolyzed sugar has high optical purity and rate of conversion of sugar and acid and short fermentation period; in addition, the semicontinuous intermittent fermentation way saves the time for preparing seeds by a continuous reladling and subculturing method, shortens the fermentation period, enhances the fermentation strength and obtains the L-lactic acid with both relatively high rate of conversion of sugar and acid and purity.

The invention provides Bacillus sp Alg07 capable of producing an alginate lyase. The preservation number of the Bacillus sp Alg07 is CGMCC No.9391. The Bacillus sp Alg07 provided by the invention has the advantages that requirement on nutrition is low and fermentation time is short; a crude enzyme is easily prepared, and the crude enzyme can be obtained through centrifugation; the alginate lyase produced by the Bacillus sp Alg07 has high enzyme activity, the specific enzyme activity of an unpurified crude enzyme can reach 20000-40000 U/mg (563U/mL); the alginate lyase produced by the Bacillus sp Alg07 has good stability, is not obviously changed in enzyme activity after being preserved at 40 DEG C for 24 hours and is high and stable in enzyme activity at pH of 5.5-8.5; and the produced alginate lyase is capable of degrading sodium alginate to generate alginate-derived oligosaccharide with biological activity.

The invention belongs to the field of biological engineering and is aimed for solving the problem of mass scale plant diseases caused by fungus. The preparing process comprises subjecting a strong of Bacillus firmus (CGMCC No.0924) to second level fermentation culture under suitable condition, then carrying out filtering, salting out and column chromatography treatment.

The invention discloses a genetic engineering strain for producing phenazine-1-carboxylic acid, which is produced by taking pseudomonas chlororaphis as a culture, as well as application of the genetic engineering strain; the genetic engineering strain is obtained by knocking out a phzH gene in pseudomonas chlororaphis genome. The genetic engineering strain for producing phenazine-1-carboxylic acid is finally prepared by deleting the phzH gene in the genome of the strain by virtue of insertion mutation or marker-less deletion from pseudomonas chlororaphis HT66 CCTCC NO: M2013467 which can naturally secrete phenazine-1-formamide as well as derivatives of the pseudomonas chlororaphis so as to convert a secondary metabolite from the phenazine-1-formamide into the phenazine-1-carboxylic acid. The invention also discloses a preparation method and a detection method of the fungicide.

The present invention discloses Agrobacteriumsp. having free-living nitrogen fixing ability, wherein a classification name of the Agrobacteriumsp. is Agrobacteriumsp. Ymu6-2, the Agrobacteriumsp. is preserved in the China General Microbiological Culture Collection Center (CGMCC), and a preservation number is CGMCC No.5007. The Agrobacteriumsp. having free-living nitrogen fixing ability in the present invention has the following advantages that: high nitrogen fixing ability is provided; high concentration Cd growth can be resisted; indole-3-acetic acid can be secreted to produce iron atoms; with the prepared microbial agent, over-accumulated plant growth can be significantly promoted, biomass of over-accumulated plants can be increased, a heavy metal enrichment coefficient and a heavy metaltransfer coefficient of over-accumulated plants can be substantially increased, soil ecology environment can be improved, and advantages of environment-friendliness and low cost are provided.

The invention relates to a preparation method of a fused protein of human serum albumin and mutant human granulocyte colony stimulating factor, and the product thereof, belonging to the technical field of long-effetive recombinant fused protein drugs. Human serum albumin(HSA) cDNA and mutant human granulocyte colony stimulating factor(hGCSF) cDNA are directly connected, without adding any connecting peptide therevetween, obtaining HAS- hGCSFm cDNA which is then integrated with a cell of the host to express. The fused protein of the invention comprises a first region with at least 85% of the sequence congenetic with human serum albumin and a second region with at least 85% of the sequence congenetic with the mutant human granulocyte colony stimulating factor, and the two regions are directly connected without any connecting peptide therebetween. Under the premise of not being changed in characteristics, the fused protein is capable of the substitution, deletion or addition of specific amino acid residues. The host cell can be bacteria, barm, insect cell, zooblast, plant cell, etc. The fused protein maintains the physiological characteristics of the mutant human granulocyte colony stimulating factor and prolonges the half life of the mutant human granulocyte colony stimulating factor within human body; therefore the fused protein is of good application prospect in pharmacy.

The invention provides a novel algin lyase producing strain, namely Acinetobacter juni. X8 (which is preserved in the China Center for Type Culture Collection, wherein the preservation number is CCTCCC No: M 209110 and the preservation time is May 20, 2009) and application thereof in preparing algin lyase. The Acinetobacter juni. X8 has the following advantages: (1) the nutritional requirement is simple, the cultivation is easy, the generation time is short, and the fermentation cultivation time is short; (2) intracellular crude enzyme solution is simple to prepare, and a centrifugal collected thallus can be shattered directly after being added into buffer solution; (3) the algin lyase prepared from the Acinetobacter juni. X8 has higher enzyme activity, and unseparated and unpurified crude enzyme solution can reach 53.9 U/mg (157.3 U/mL); (4) the reaction conditions required by the enzyme enzymolysis algin is mild, and the acting time is short; and (5) the algin lyase has good stability, can keep higher enzyme activity (more than 97 percent) after being preserved for 5 days at a temperature of less than or equal to 4 DEG C, and is stable for 8 hours under a condition of which the pH is between 7.7 and 9.0.

The invention provides a novel agarase generating strain (roseobactersp.zjut) and application thereof in the preparation of agaro-oligosaccharide. The roseobactersp.zjut is preserved in the China Center for Type Culture Collection, the collection number is CCTCC No. M 209292, and the preservation date is December 3, 2009. The roseobactersp.zjut and the application thereof in the preparation of the agaro-oligosaccharide have the advantages that: (1) the roseobactersp.zjut of the invention has low requirements on nutrition and can be easily cultured; (2) agarase generated by the roseobactersp.zjut is an extracellular enzyme, separation and purification are convenient, and cell breakage is not required; (3) the roseobactersp.zjut has high agarase generating activity, and the activity of crude agarase liquid which is not separated and purified can reach 215.8U/ml under optimized conditions; (4) the agarase generated by the roseobactersp.zjut degrades agar under mild reaction conditions, and the reaction time is short; and (5) the agarase in the invention has high stability and basically has no enzyme activity loss (inactivation efficiency is less than or equal to 5 percent) after being stored in a refrigerator for 7 days at the temperature of less than 4 DEG C.

The invention discloses a method for making fuel by using sea water as a medium and a special strain. The special strain is holomonas (Halomonas sp.)LS21, of which the collection number is CGMCCNo.6593. Experiments show that the Halomonas sp.LS21 and the recombinant strain thereof can produce hydrocarbons mainly comprising alkane, olefin and long-chain fatty acid by using natural sea water as a fermenting medium and using cheap carbon materials and nitrogen sources such as pre-treated cellulose, hemicellulose, waste oils and fats and kitchen waste as substrate. The separated hydrocarbons can be used as biofuel, and continuous fermentation without sterilization can be realized. The holomonas and the recombinant strain thereof have low requirement on nutrients. The fermentation process can go continuously without sterilization. The method is simple and easy to control and low in cost, and has a great prospect in industrial application.

The invention discloses a fused protein from human brain natriuretic peptide(BNP)2 and human serum albumin (HSA) and the preparation method thereof, belonging to the technical field of long-effetive recombinant fused protein drugs. The invention introduces OE-PCR technology to splice two BNP cDNAs(called (BNP)2 for short) and HAS cDNA, without adding any connecting peptide therebetween, obtaining fused gene(BNP)2-HSA cDNA which is then integrated with the chromosome of the host and expresses in the expression system of the host. The fused protein of the invention comprises a first region with at least 85% of the sequence congenetic with human brain natriuretic peptide and a second region with at least 85%of the sequence congenetic with human serum albumin. Under the premise of not being changed in characteristics, the fused protein is capable of the substitution, deletion or addition of specific amino acid residues. The fused protein maintains the physiological characteristics and improves the solubility of human brain natriuretic peptide and prolongs the half life of human brain natriuretic peptide within human body; therefore the fused protein is of good application prospect in pharmacy.

The invention discloses bacillus velezensis HY19 and application thereof. The strain Bacillus velezensis HY19 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation date is January 4, 2021, and the preservation number is CGMCC No.21590. The strain can generate various water-soluble and volatile antibacterial substances, can effectively antagonize various plant pathogenic fungi, is wide in antibacterial spectrum and strong in antibacterial effect, has a relatively good biological prevention and treatment effect on flue-cured tobacco brown spot, is harmless to the ecological environment, and is not easy to cause drug resistance of pathogens. The strain has the characteristics of high breeding speed, high environmental adaptability, simple nutritional requirements, wide disease-resistant spectrum and the like, and is a novel biocontrol microorganism which is safe, efficient and capable of preventing and treating fungal diseases of plants in a broad-spectrum manner. The biocontrol microbial agent of the invention is simple in preparation method, easy for industrial production, and has good development and application prospects.

The invention relates to a manufacture method and product for confluence albumen of human alpha-2 interferon and human serum albumin that uses superposing PCR technology, connecting IFN alpha-2 cDNA and HAS cDNA, with out any connecting peptide to gain IFN alpha-2 HSA cDNA melting gene to be integrated into host chromosome to take expression. The confluence albumen includes the first area of at least 85% sequence same source as human beta-interferon and the second area of at least 85% sequence of same source of human serum albumin. The invention has good application prospect in medicine field.

The invention discloses an aspergillus niger which is classified and named aspergillus niger M1 with the preservation number being CCTCC NO: M2014421. The preservation date is September 23nd, 2014, and the preservation department is China Center for Type Culture Collection. Alpha-glucosidase produced by the aspergillus niger M1 strain is endoenzyme, and the aspergillus niger M1 strain can produce isomaltose hypgather containing more than 65% of active trisaccharide (IG+P+IG3) under the condition of high temperature. The required reaction time of preparing IMO-500 type isomaltose hypgather containing 35% of active trisaccharide is only half of the reaction time of preparing the isomaltose hypgather containing more than 65% of active trisaccharide. The alpha-glucosidase produced by the strain has advantages of excellent temperature characteristic, short glucoside conversion time, high content of the active trisaccharide in the product and the like.

The invention relates to a new separated bacterial strain of mortierella alpine (Mortierella Alpina) and an application thereof. Particularly, the invention relates to CGMCC No.6254, offspring thereof, culture and/or mutant strain and a method and application in preparing arachidonic acid by using the bacterial strain, offspring thereof, culture and/or mutant strain. The separated bacterial strain is a natural bacterial strain, and can stably produce arachidonic acid with a yield as high as 14.32g/L.

The invention discloses Bacillus sp.W2017 which is preserved in the China Center for Type Culture Collection in the Wuhan University on the Bayi Road, Hongshan District, Wuhan, Hubei, China on May 2,2017, the zip code is 430072, and the preservation number is CCTCC No: M 2017226. The invention further relates to application of the agar degrading enzyme generation Bacillus sp.W2017. The agar degrading enzyme generation Bacillus sp.W2017 is a Gram-negative bacterium which is high in enzyme activity, stable in enzyme activity and high in enzyme yield.